Coulie Bernard 4

What Happened

• Coulie Bernard, President, CEO and Director of Pliant Therapeutics (PLRX), was granted a derivative award covering 1,230,000 shares on 2026-01-22. The filing reports $0.00 per share for the award (derivative instrument), indicating no immediate cash paid by the insider.

Key Details

• Transaction type: Award/Grant (code A) of a derivative instrument representing 1,230,000 shares.
• Transaction date: 2026-01-22; Filing date: 2026-01-26 (appears timely under Form 4 reporting rules).
• Reported price: $0.00 (derivative award—no cash purchase recorded).
• Vesting: 1/48th of the shares subject to the option vest and become exercisable in substantially equal monthly installments beginning January 1, 2026, subject to continued service (per footnote).
• Shares owned after transaction: Not specified in the provided filing.

Context

• This is a compensation award (an option-style derivative per the footnote) rather than an open-market purchase or sale. The award vests monthly over four years, meaning the CEO must remain employed for shares/options to become exercisable. Such grants are common executive compensation and do not by themselves indicate an immediate purchase or sale of stock.